Literature DB >> 9705080

Aromatase expression of human osteoblast-like cells.

M Shozu1, E R Simpson.   

Abstract

Estrogen plays a major role in bone mineral homeostasis, maintaining a balance between bone formation and bone resorption not only in women but also in men. Extraglandular aromatization of circulating androgen is the major source of estrogen in post-menopausal women and men. In order to assess the capacity of bone cells as a local source of estrogen, osteoblast-like cells (OLCs) were obtained from human fetal bone in mid-trimester by the explant method and by mechanical disaggregation. The integrity of OLCs was confirmed by their ability to produce alkaline phosphatase and osteocalcin in response to vitamin D3 and also by their ability to deposit mineral. Aromatase activity was assessed by the formation of estrone from [1,2,6,7-3H]androstenedione and by the release of tritium from [1beta-3H]androstenedione into [3H]water. Formation of estrone was confirmed by thin layer chromatography (TLC) in OLCs stimulated with dexamethasone (DEX) + oncostatin M. The aromatase activity was 10 x higher in non-passaged OLCs than in passaged cells in the presence or absence of the stimulants (DEX + IL-1beta). The apparent Km and Vmax estimated by the release of [3H]water was 5.8+/-0.6 nM and 10.8+/-1.4 pmol/mg per 6 h in the presence of DEX + IL-1beta. The effects of several stimulants on aromatase activity in OLCs were examined: serum, IL-1beta, TNFalpha and type I cytokines stimulated activity in the presence of DEX, while PMA and PMA + dibutyryl cAMP did not. To confirm the expression of aromatase in OLCs, cells prepared from periosteal membranes were also examined: These cells in culture possessed aromatase activity corresponding to OLCs prepared from bone specimens. Moreover, the fresh periosteum expressed aromatase at higher levels than that of metaphyseal specimens. The aromatase gene employs several different promoters (I.1, 1.2, I.3, I.4, I.5, I.6, 2a, 1f and PII) and the usage of these promoters is known to be controlled in a tissue-specific fashion. Accordingly, promoter usage in OLCs and fetal long bone (tibia) tissue was examined using the 5' rapid amplification of cDNA ends (RACE) technique. The major promoter used was I.4, not only in stimulated and non-stimulated OLCs, but also in fetal tibia. Some minor transcripts were also found: 1f (brain-specific promoter), PII and I.6 in OLCs stimulated by DEX + IL-1beta, and PII and I.3 in OLCs stimulated by DEX + serum. Fetal tibia also expressed I.3 (15%) and I.6 (10%). Thus, regulation and promoter usage in OLCs was quite different from other tissues known as estrogen sources including adipose tissue, ovary and placenta. These results suggest that bone is an extraglandular source of local estrogen which plays an important role in bone mineral metabolism through autocrine and paracrine actions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9705080     DOI: 10.1016/s0303-7207(98)00069-0

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  12 in total

1.  The gene for aromatase, a rate-limiting enzyme for local estrogen biosynthesis, is a downstream target gene of Runx2 in skeletal tissues.

Authors:  Jae-Hwan Jeong; Youn-Kwan Jung; Hyo-Jin Kim; Jung-Sook Jin; Hyun-Nam Kim; Sang-Min Kang; Shin-Yoon Kim; Andre J van Wijnen; Janet L Stein; Jane B Lian; Gary S Stein; Shigeaki Kato; Je-Yong Choi
Journal:  Mol Cell Biol       Date:  2010-03-15       Impact factor: 4.272

2.  Bone and body composition response to testosterone therapy vary according to polymorphisms in the CYP19A1 gene.

Authors:  Lina E Aguirre; Georgia Colleluori; David Robbins; Richard Dorin; Vallabh O Shah; Rui Chen; Irum Zeb Jan; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  Endocrine       Date:  2019-07-19       Impact factor: 3.633

3.  Testosterone increases bone mineral density in female-to-male transsexuals: a case series of 15 subjects.

Authors:  Adrian Turner; Tai C Chen; Tom W Barber; Alan O Malabanan; Michael F Holick; Vin Tangpricha
Journal:  Clin Endocrinol (Oxf)       Date:  2004-11       Impact factor: 3.478

4.  Increases in bone mineral density in response to oral dehydroepiandrosterone replacement in older adults appear to be mediated by serum estrogens.

Authors:  Catherine M Jankowski; Wendolyn S Gozansky; John M Kittelson; Rachael E Van Pelt; Robert S Schwartz; Wendy M Kohrt
Journal:  J Clin Endocrinol Metab       Date:  2008-09-23       Impact factor: 5.958

Review 5.  Understanding and management of male breast cancer: a critical review.

Authors:  Kartikeya Pant; Udayan Dutta
Journal:  Med Oncol       Date:  2007-12-12       Impact factor: 3.064

6.  Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors.

Authors:  Philip Lazarus; Dongxiao Sun
Journal:  Drug Metab Rev       Date:  2010-02       Impact factor: 4.518

7.  CYP19 and ESR1 gene polymorphisms: response of the bone mineral density in post-menopausal women to hormonal replacement therapy.

Authors:  Laura Masi; Silva Ottanelli; Rossella Berni; Ettore Cacudi; Francesca Giusti; Gemma Marcucci; Loredana Cavalli; Caterina Fossi; Francesca Marini; Simone Ciuffi; Annalisa Tanini; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-01

8.  Aromatase activity and bone loss in men.

Authors:  Daniela Merlotti; Luigi Gennari; Konstantinos Stolakis; Ranuccio Nuti
Journal:  J Osteoporos       Date:  2011-06-24

9.  Eurycoma longifolia: Medicinal Plant in the Prevention and Treatment of Male Osteoporosis due to Androgen Deficiency.

Authors:  Nadia Mohd Effendy; Norazlina Mohamed; Norliza Muhammad; Isa Naina Mohamad; Ahmad Nazrun Shuid
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-15       Impact factor: 2.629

10.  TGF-β1 regulation of estrogen production in mature rat Leydig cells.

Authors:  Man-Li Liu; Huan Wang; Zong-Ren Wang; Yu-Fen Zhang; Yan-Qiu Chen; Fang-Hong Zhu; Yuan-Qiang Zhang; Jing Ma; Zhen Li
Journal:  PLoS One       Date:  2013-03-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.